961-68-2Relevant articles and documents
-
Bunnett,Davis
, p. 4337 (1958)
-
-
Ross,Kuntz
, p. 3000 (1954)
-
Bain,Ouellet
, p. 646,650, 653 (1951)
-
Ogata,Okano
, (1952)
-
Incorporation of: N -phenyl in poly(benzimidazole imide)s and improvement in H2O-absorbtion and transparency
Qian, Guangtao,Dai, Fengna,Chen, Haiquan,Wang, Mengxia,Hu, Mengjie,Chen, Chunhai,Yu, Youhai
, p. 3770 - 3776 (2021/02/03)
5-Amine-2-(4-amino-benzene)-1-phenyl-benzimidazole (N-PhPABZ) was successfully synthesized and polymerized with 3,3′,4,4′-biphenyl tetracarboxylic dianhydride (BPDA) to obtain a novel N-phenyl-poly(benzimidazole imide) (N-Ph-PBII). The successful incorporation of N-phenyl addressed the issue of high H2O-absorption of traditional PBIIs while retained the superheat resistance property. The resulting N-Ph-PBII possessed a high glass-transition temperature (Tg) up to 425 °C and a low affinity for water of 1.4%. Furthermore, the loose molecular packing and noncoplanar structures led to an increase in optical transparency for the modified PBII.
Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer
Tokay, Esra,Güng?r, Tu?ba,Hac?o?lu, Nelin,?nder, Ferah C?mert,Gülhan, ünzile Güven,Tok, Tu?ba Ta?k?n,?elik, Ayhan,Ay, Mehmet,K??kar, Feray
, (2019/12/24)
Prodrugs for targeted tumor therapies have been extensively studied in recent years due to not only maximising therapeutic effects on tumor cells but also reducing or eliminating serious side effects on healthy cells. This strategy uses prodrugs which are safe for normal cells and form toxic metabolites (drugs) after selective reduction by enzymes in tumor tissues. In this study, prodrug candidates (1-36) containing nitro were designed, synthesized and characterized within the scope of chemical experiments. Drug-likeness properties of prodrug candidates were analyzed using DS 2018 to investigate undesired toxicity effects. In vitro cytotoxic effects of prodrug canditates were performed with MTT assay for human hepatoma cells (Hep3B) and prostate cancer cells (PC3) and human umbilical vein endothelial cells (HUVEC) as healthy control. Non-toxic compounds (3, 5, 7, 10, 12, 15, 17, 19 and 21–23), and also compounds (1, 2, 5, 6, 9, 11, 14, 16, 20 and 24) which had low toxic effects, were selected to examine their suitability as prodrug canditates. The reduction profiles and kinetic studies of prodrug/Ssap-NtrB combinations were performed with biochemical analyses. Then, selected prodrug/Ssap-NtrB combinations were applied to prostate cancer cells to determine toxicity. The results of theoretical, in vitro cytotoxic and biochemical studies suggest 14/Ssap-NtrB, 22/Ssap-NtrB and 24/Ssap-NtrB may be potential prodrug/enzyme combinations for nitroreductase (Ntr)-based prostate cancer therapy.
Neutral Cyclometalated Iridium(III) Complexes Bearing Substituted N-Heterocyclic Carbene (NHC) Ligands for High-Performance Yellow OLED Application
Liu, Bingqing,Jabed, Mohammed A.,Guo, Jiali,Xu, Wan,Brown, Samuel L.,Ugrinov, Angel,Hobbie, Erik K.,Kilina, Svetlana,Qin, Anjun,Sun, Wenfang
, p. 14377 - 14388 (2019/11/03)
The synthesis, crystal structure, and photophysics of a series of neutral cyclometalated iridium(III) complexes bearing substituted N-heterocyclic carbene (NHC) ancillary ligands ((CN)2Ir(R-NHC), where CN and NHC refer to the cyclometalating ligand benzo[h]quinoline and 1-phenylbenzimidazole, respectively) are reported. The NHC ligands were substituted with electron-withdrawing or -donating groups on C4′ of the phenyl ring (R = NO2 (Ir1), CN (Ir2), H (Ir3), OCH3 (Ir4), N(CH3)2 (Ir5)) or C5 of the benzimidazole ring (R = NO2 (Ir6), N(CH3)2 (Ir7)). The configuration of Ir1 was confirmed by a single-crystal X-ray diffraction analysis. The ground- and excited-state properties of Ir1-Ir7 were investigated by both spectroscopic methods and time-dependent density functional theory (TDDFT) calculations. All complexes possessed moderately strong structureless absorption bands at ca. 440 nm that originated from the CN ligand based 1π,π*/1CT (charge transfer)/1d,d transitions and very weak spin-forbidden 3MLCT (metal-to-ligand charge transfer)/3LLCT (ligand-to-ligand charge transfer) transitions beyond 500 nm. Electron-withdrawing substituents caused a slight blue shift of the 1π,π*/1CT/1d,d band, while electron-donating substituents induced a red shift of this band in comparison to the unsubstituted complex Ir3. Except for the weakly emissive nitro-substituted complexes Ir1 and Ir6 that had much shorter lifetimes (≤160 ns), the other complexes are highly emissive in organic solutions with microsecond lifetimes at ca. 540-550 nm at room temperature, with the emitting states being predominantly assigned to 3π,π*/3MLCT states. Although the effect of the substituents on the emission energy was insignificant, the effects on the emission quantum yields and lifetimes were drastic. All complexes also exhibited broad triplet excited-state absorption at 460-700 nm with similar spectral features, indicating the similar parentage of the lowest triplet excited states. The highly emissive Ir2 was used as a dopant for organic light-emitting diode (OLED) fabrication. The device displayed a yellow emission with a maximum current efficiency (ηc) of 71.29 cd A-1, a maximum luminance (Lmax) of 32747 cd m-2, and a maximum external quantum efficiency (EQE) of 20.6%. These results suggest the potential of utilizing this type of neutral Ir(III) complex as an efficient yellow phosphorescent emitter.